###### Significance of this study

What is already known about this subject?
=========================================

-   The survival-to-discharge rate of out-of-hospital cardiac arrest (OHCA) ranges from 1% to 20% and requires improvement.

-   Pharmacotherapy plays an important role in the primary prevention of OHCA, including reducing risk factors for ischemic heart disease and preventing ventricular arrhythmia.

-   Questions have been raised about whether preceding medications improve or worsen prognosis after successful resuscitation.

What are the new findings?
==========================

-   Preceding statin use was independently associated with better survived events in patients with OHCA (OR=2.09, p=0.028).

-   Preceding digoxin use was adversely associated with survived events in patients with OHCA (OR=0.39, p=0.028).

-   Preceding use of antiarrhythmics had no effect on the survived events in patients with OHCA.

How might these results change the focus of research or clinical practice?
==========================================================================

-   The most effective management of OHCA is to prevent its occurrence by lowering the risk of ischemic heart disease and preventing ventricular arrhythmia; therefore, our results suggest that more attention needs to be paid to the preceding medications because of their potential association with survival after OHCA.

Introduction {#s1}
============

Out-of-hospital cardiac arrest (OHCA) is a profound clinical challenge worldwide. The reported incidence of OHCA ranges from 19 to 150 per 100 000 person-years, and the survival to discharge rate of OHCA is poor, at 1--20%.[@R1] The majority of OHCA are attributable to ischemic heart disease,[@R2] [@R3] followed by structural heart disease,[@R4] and primary electrical disease.[@R5] In addition to an effective and rapid chain of care for OHCA, reducing the risk of developing ischemic heart disease and preventing ventricular arrhythmia prior to OHCA greatly improve outcome.[@R6] Pharmacotherapy plays an important role in pre-OHCA managements, including anticoagulants for preventing myocardial infarction, antihypertensive and antidiabetic drugs for treating underlying risk factors of ischemic heart disease, and antiarrhythmic drugs for treating and preventing ventricular arrhythmia.[@R6]

While medications play a role in the primary prevention of OHCA, once sudden cardiac arrest occurs, it is unclear whether the preceding medications improve survival after resuscitation. In a prospective multicenter study including 874 patients with prehospital cardiac arrest, the antecedent use of antiarrhythmic drugs were associated with poor emergency room survival.[@R7] Another study found that class III antiarrhythmic drugs, such as sotalol, could reduce arrhythmia recurrences but not total mortality after sudden cardiac arrest.[@R8] As evidence has been inconsistent, the aim of this study is to analyze the association of preceding medications with the resuscitation outcome in patients with OHCA.

Methods {#s2}
=======

Subjects {#s2a}
--------

Subjects who presented to a tertiary care hospital by emergency medical service (EMS) after experiencing OHCA between January 2006 and June 2011 were included. Patients were excluded for any of the following: (1) age \<18 years, (2) significant signs of death, (3) refusal of resuscitation, (4) traumatic cardiac arrest, or (5) implantable cardioverter defibrillator. Significant sign of death refers to postmortem changes, including rigor mortis, livor mortis, algor mortis, cadaveric spasm, decomposition, mummification, and skeletonization.[@R9] Traumatic cardiac arrest refers to cardiac arrest directly caused by trauma, such as blunt, penetrating, or burn injury.[@R10]

This retrospective study was ethically approved by the local Institutional Review Board.

Data collection {#s2b}
---------------

The Utstein template was used for data collection.[@R10] From EMS and hospital medical records, we retrospectively collected demographic characteristics, past medical histories, prehospital and in-hospital care data, and information on medication use during the 2 weeks prior to OHCA. Prehospital care data included place of arrest; presence of witness and bystander cardiopulmonary resuscitation (CPR); time of calls, EMS dispatching, EMS arrival at the scene, EMS starting CPR, EMS departing the scene, and EMS arrival at the hospital; use of automated external defibrillator (AED) and initial rhythm of AED; administration of advanced airway management by EMS; and administration of epinephrine by EMS. In-hospital care data included initial rhythm of 12-lead ECG, medication use during CPR, presence of ventricular tachycardia (VT) or ventricular fibrillation (VF) during CPR, and probable etiology of OHCA.

Information regarding medications that were used continuously for at least 2 weeks prior to OHCA was collected from ambulatory and insurance records of each subject. Data were collected only for drugs that have a previously reported association with sudden death and/or significant cardiovascular or respiratory effects, including antiarrhythmic drugs (class I: sodium channel blockers; class II: β-blockers; class III: potassium channel blockers; class IV: calcium channel blockers), cardiovascular drugs (aspirin, clopidogrel, statins, nitroglycerin, Q10, cilostazol), antidiabetic drugs (insulin, oral hypoglycemic agent), antihypertensive drugs (α-blockers, ACE inhibitors, angiotensin II receptor blockers, diuretics), and other relevant drugs such as warfarin, magnesium sulfate, erythromycin, N-acetylcysteine, steroid, digoxin, and QT-prolonging agents.

Statistical analysis {#s2c}
--------------------

The primary outcome was the success of resuscitation in the emergency department, represented by the rate of survived events. A survived event, as defined by the Utstein template, is the sustained return of spontaneous circulation (ROSC) until admission and handover to the receiving hospital.[@R10] Continuous data are presented as mean with SD, and categorical data presented as count with percentage. The differences between patients with and without survived events for continuous and categorical data were tested using the two-sample t-test and χ^2^ test, respectively. Multivariable logistic regression analyses were performed to evaluate the predictors of survived events using variables with a p value of \<0.1 in the univariable analysis. A two-tailed p value of \<0.05 indicated statistical significance. All statistical analyses were performed using IBM SPSS Statistics for Windows, V.19.0 (Armonk, New York, USA).

Results {#s3}
=======

A total of 1381 patients with OHCA were included ([figure 1](#JIM2016000264F1){ref-type="fig"}). Among these patient, 552 (40.0%) patients achieved ROSC and 463 (33.5%) had survived events after resuscitation. Ninety-six (7.0%) patients survived until discharge and 20 (1.4%) had favorable neurological outcomes at discharge defined as a cerebral performance category (CPC) of ≤2.

![Outcomes of the included OHCA patients. CPC, cerebral performance category; EMS, emergency medical service; OHCA, out-of-hospital cardiac arrest; ROSC, return of spontaneous circulation.](jim-2016-000264f01){#JIM2016000264F1}

[Table 1](#JIM2016000264TB1){ref-type="table"} lists the comparison of demographic characteristics and medical histories between the patients with and without survived events. There was no difference regarding sex and medical histories between the two groups. Patients with survived events were older than those without survived events (68.8 vs 66.4 years, p=0.01).

###### 

Demographic characteristics of the included patients with out-of-hospital cardiac arrest

                             No survived event (n=918)   Survived event (n=463)   p Value
  -------------------------- --------------------------- ------------------------ ---------
  Age (year)†                66.4 (17.4)                 68.8 (15.1)              0.010\*
  Sex                                                                             
   Female                    332 (36.2)                  170 (36.7)               0.841
   Male                      586 (63.8)                  293 (63.3)               
  Medical history                                                                 
   Diabetic mellitus         196 (21.4)                  113 (24.4)               0.198
   Hypertension              268 (29.2)                  148 (32.0)               0.289
   Hyperlipidemia            19 (2.1)                    10 (2.2)                 0.912
   Heart failure             59 (6.4)                    24 (5.2)                 0.359
   Arrhythmia                21 (2.3)                    17 (3.7)                 0.138
   Coronary artery disease   176 (19.2)                  97 (21.0)                0.433
   Cancer                    94 (10.2)                   50 (10.8)                0.748
   COPD/asthma               54 (5.9)                    31 (6.7)                 0.553
   Stroke                    97 (10.6)                   65 (14.0)                0.058
   Chronic liver disease     32 (3.5)                    15 (3.2)                 0.812
   Chronic kidney disease    84 (9.2)                    52 (11.2)                0.221

\*p\<0.05.

†Data were presented as count (percentage) or mean (SD).

COPD, chronic obstructive pulmonary disease.

Clinical information regarding prehospital and in-hospital care is provided in [table 2](#JIM2016000264TB2){ref-type="table"}. Patients with survived events had significantly greater proportion of witnessed arrests (55.9% vs 32.6%, p\<0.001), shorter duration between time of call and time of EMS arrival at the scene (4.9 vs 5.2 min, p=0.04), shorter duration between time of call and time of EMS departing the scene (16.1 vs 17.1 min, p=0.004), shorter duration between time of call and time of EMS arrival at the hospital (24.7 vs 26.0 min, p\<0.001), greater proportion of shockable initial AED rhythm (13.2% vs 8.0%, p=0.005), and a greater proportion of patients received advanced airway management by EMS (31.7% vs 24.7%, p=0.006) than those without survived events. After arrival at the emergency department, significantly more patients with survived events had shockable initial 12-lead ECG rhythm (8.0% vs 3.8%, p=0.001), had received atropine (30.0% vs 20.9%, p\<0.001), had received MgSO~4~ (4.3% vs 1.5%, p=0.002), had presence of VT/VF during CPR (27.0% vs 19.7%, p=0.002) and fewer had cardiac etiology of OHCA (51.4% vs 72.3%, p\<0.001) than those without survived events.

###### 

Clinical information of patients

                                         No survived event (n=918)   Survived event (n=463)   p Value
  -------------------------------------- --------------------------- ------------------------ -----------
  Prehospital                                                                                 
   Arrest at home                        76 (8.3)                    34 (7.3)                 0.544
   Witnessed arrest                      299 (32.6)                  259 (55.9)               \<0.001\*
   Bystander CPR                         118 (12.9)                  73 (15.8)                0.139
  Response time (min)†                                                                        
   Time to EMS arrival at the scene      5.2 (2.4)                   4.9 (2.4)                0.040\*
   Time to EMS starting CPR              9.3 (4.9)                   9.2 (5.1)                0.675
   Time to EMS departing the scene       17.1 (6.0)                  16.1 (6.2)               0.004\*
   Time to EMS arrival at the hospital   26.0 (6.5)                  24.7 (7.0)               \<0.001\*
  AED                                                                                         0.005\*
   No AED use                            44 (4.8)                    27 (5.8)                 
   Initial AED rhythm non-shockable      801 (87.3)                  375 (81.0)               
   Initial AED rhythm shockable          73 (8.0)                    61 (13.2)                
  Advanced airway management by EMS      227 (24.7)                  147 (31.7)               0.006\*
  Epinephrine given by EMS               175 (19.1)                  101 (21.8)               0.227
  Hospital                                                                                    
  Initial 12-lead ECG rhythm shockable   35 (3.8)                    37 (8.0)                 0.001\*
  Medications                                                                                 
   Epinephrine                           835 (91.0)                  415 (89.6)               0.427
   Atropine                              192 (20.9)                  139 (30.0)               \<0.001\*
   Sodium bicarbonate                    273 (29.7)                  151 (32.6)               0.274
   Amiodarone                            114 (12.4)                  60 (13.0)                0.775
   MgSO~4~                               14 (1.5)                    20 (4.3)                 0.002\*
   Lidocaine                             14 (1.5)                    7 (1.5)                  0.985
  VT/VF during CPR                       181 (19.7)                  125 (27.0)               0.002\*
  Cardiac etiology                       664 (72.3)                  238 (51.4)               \<0.001\*

\*p\<0.05.

†Data were presented as count (percentage) or mean (SD).

AED, automated external defibrillator; CPR, cardiopulmonary resuscitation; EMS, emergency medical service; VF, ventricular fibrillation; VT, ventricular tachycardia.

Comparison of medications uses during the 2-week period prior to OHCA between patients with and without survived events revealed that significantly more patients who survived OHCA were receiving class II antiarrhythmic drugs (5.6% vs 3.2%, p=0.028), statins (5.0% vs 2.8%, p=0.043), N-acetylcysteine (1.7% vs 0.5%, p=0.040), and fewer were receiving digoxin (1.7% vs 3.7%, p=0.044) compared with those who did not survive ([table 3](#JIM2016000264TB3){ref-type="table"}).

###### 

Medication uses during the 2 weeks preceding out-of-hospital cardiac arrest

                                  No survived event (n=918)   Survived event (n=463)   p Value
  ------------------------------- --------------------------- ------------------------ ---------
  Antiarrhythmics                                                                      
   Class I                        6 (0.7)                     3 (0.6)                  1.000
   Class II                       29 (3.2)                    26 (5.6)                 0.028\*
   Class III                      7 (0.8)                     3 (0.6)                  1.000
   Class IV                       63 (6.9)                    34 (7.3)                 0.741
  Aspirin                         54 (5.9)                    31 (6.7)                 0.553
  Clopidogrel                     23 (2.5)                    16 (3.5)                 0.314
  Statin                          26 (2.8)                    23 (5.0)                 0.043\*
  Nitroglycerin                   23 (2.5)                    15 (3.2)                 0.431
  Insulin                         10 (1.1)                    8 (1.7)                  0.323
  Oral hypoglycemic agents        65 (7.1)                    42 (9.1)                 0.191
  α-Blockers                      17 (1.9)                    16 (3.5)                 0.065
  Angiotensin receptor blockers   58 (6.3)                    40 (8.6)                 0.113
  ACE inhibitors                  19 (2.1)                    9 (1.9)                  0.875
  Diuretics                       97 (10.6)                   52 (11.2)                0.707
  Warfarin                        9 (1.0)                     4 (0.9)                  1.000
  Magnesium                       14 (1.5)                    9 (1.9)                  0.566
  Erythromycin                    2 (0.2)                     1 (0.2)                  1.000
  N-acetylcysteine                5 (0.5)                     8 (1.7)                  0.040\*
  Steroid                         17 (1.9)                    8 (1.7)                  0.870
  Digoxin                         34 (3.7)                    8 (1.7)                  0.044\*
  Theophylline                    39 (4.2)                    19 (4.1)                 0.899
  Cilostazol                      5 (0.5)                     1 (0.2)                  0.670
  QT-prolonging drugs             10 (1.1)                    5 (1.1)                  0.987

Data were presented as count (percentage).

\*p\<0.05.

Results of multivariable logistic regression model for the predictors of survived events are summarized in [table 4](#JIM2016000264TB4){ref-type="table"}. After adjusting for other variables, several variables were independent predictors of survived events, including witnessed arrest (OR=2.18, 95% CI 1.70 to 2.80, p\<0.001), response time between call and EMS arrival at the hospital (OR=0.97, 95% CI 0.95 to 0.98, p\<0.001), performance of advanced airway management by EMS (OR=1.70, 95% CI 1.27 to 2.26, p\<0.001), administration of atropine (OR=1.68, 95% CI 1.26 to 2.23, p\<0.001), administration of MgSO~4~ (OR=3.13, 95% CI 1.43 to 6.88, p=0.004), prehospital ROSC (OR=6.89, 95% CI 3.27 to 14.54, p\<0.001), and cardiac etiology (OR=0.30, 95% CI 0.23 to 0.39, p\<0.001). Regarding medication use preceding OHCA, the use of statins was an independent positive predictor (OR=2.09, 95% CI 1.08 to 4.03, p=0.028) and the use of digoxin was a negative predictor (OR=0.39, 95% CI 0.16 to 0.90, p=0.028) of survived events.

###### 

Multivariable logistic regression model for the predictors of survival events

                                         OR     95% CI          p Value
  -------------------------------------- ------ --------------- -----------
  Age (year)                             1.01   1.00 to 1.01    0.066
  Witnessed arrest                       2.18   1.70 to 2.80    \<0.001\*
  Time to EMS arrival at the hospital    0.97   0.95 to 0.98    \<0.001\*
  Advanced airway management by EMS      1.70   1.27 to 2.26    \<0.001\*
  AED                                                           
   No AED use                            --     --              0.128
   Initial AED rhythm non-shockable      0.65   0.41 to 1.02    0.063
   Initial AED rhythm shockable          0.81   0.43 to 1.54    0.529
  Initial 12-lead ECG rhythm shockable   1.57   0.83 to 2.98    0.170
  Atropine                               1.68   1.26 to 2.23    \<0.001\*
  MgSO~4~                                3.13   1.43 to 6.88    0.004\*
  VT/VF during CPR                       1.24   0.88 to 1.74    0.221
  Prehospital ROSC                       6.89   3.27 to 14.54   \<0.001\*
  Cardiac etiology                       0.30   0.23 to 0.39    \<0.001\*
  Stroke                                 1.30   0.89 to 1.90    0.175
  Antiarrhythmics, class II              1.74   0.93 to 3.26    0.081
  Statin                                 2.09   1.08 to 4.03    0.028\*
  α-Blocker                              1.31   0.59 to 2.91    0.505
  N-acetylcysteine                       3.14   0.96 to 10.26   0.059
  Digoxin                                0.39   0.16 to 0.90    0.028\*

\*p\<0.05.

AED, automated external defibrillator; CPR, cardiopulmonary resuscitation; EMS, emergency medical service; ROSC, return of spontaneous circulation; VF, ventricular fibrillation; VT, ventricular tachycardia.

Discussion {#s4}
==========

Most patients with OHCA had some form of underlying heart diseases, mainly ischemic heart diseases. Primary prevention of OHCA includes optimal management of ventricular arrhythmia and reduction of risk factors for ischemic heart disease. Pharmacotherapy plays an important role in the primary prevention of OHCA; however, sufficient evidence is lacking regarding the association between medication use preceding OHCA and the resuscitation outcome. In this study, use of a statin was significantly associated with survival after OHCA (OR=2.09, 95% CI 1.08 to 4.03, p=0.028) and use of digoxin was associated with less likelihood of survival (OR=0.39, 95% CI 0.16 to 0.90, p=0.028) after adjusting for other variables.

Statins have been shown to have cardiovascular protective effects, including stabilization of atherosclerotic plaque, inhibition of systematic inflammation, antioxidative quality, improvement in endothelial function, and ability to increase nitric oxide bioavailability, which attribute to the pleiotropic and lipid-lowering effects of agents in this class.[@R11] [@R12] Some studies have observed potential antiarrhythmic effects of statins, such as improving heart rate variability and decreasing QT dispersion.[@R13] [@R14] Moreover, a meta-analysis of 25 randomized controlled trials conducted by Rahimi *et al*[@R15] reported that statin use was associated with a 10% reduction in risk of sudden cardiac death in comparison with control (OR=0.90, 95% CI 0.82 to 0.97, p=0.01). However, very few studies have analyzed the effect of statins on resuscitation outcomes after cardiac arrest. In a prospective study by Vukmir *et al*, antecedent medication use by patients with OHCA was only briefly described as use of cardiac drugs, and antihypertensive, antiarrhythmic, pulmonary, hematological, gastrointestinal, psychiatric, or antiseizure agents.[@R7] This study did not specify which agents were included as cardiac drugs, for example, cholesterol-lowering agents or statins.[@R7] Our results found that the use of statins significantly increased the rate of survived events in patients experiencing OHCA. This finding suggests that the cardioprotective effect of statins prevents cardiac arrest and cardiac death, and also might affect resuscitation outcomes of sudden cardiac arrest.

Digoxin is a standard treatment for congestive heart failure, but its cardiac safety and effect remain uncertain. In a prospective study by Teodorescu *et al* comprising 378 sudden cardiac death cases, multivariable analysis revealed that digoxin significantly increased the risk of sudden cardiac death (OR=4.74, 95% CI 2.35 to 9.53, p\<0.0001).[@R16] Conversely, a retrospective study including 6797 participants noted that digoxin was not an independent risk factor of sudden coronary death (OR=1.19, 95% CI 0.94 to 1.49, p=0.15).[@R17] These conflicting results might have been due to interaction between digoxin and other drugs that could influence digoxin concentrations, and thus affecting its activity. Consequently, the true effect size of digoxin could be underestimated or overestimated in each study.[@R18] In addition to these conflicting results, sufficient evidence is lacking in regard to the effect of digoxin on resuscitation outcomes of cardiac arrest. Our study found that digoxin use was associated with poor emergency room survival in patients with OHCA. The result suggests that the cardiac toxicity of digoxin remains when sudden cardiac arrest occurs and subsequently influences resuscitation outcomes.

While a better understating could be gained from a randomized controlled clinical study, the retrospective findings presented here could be a starting point. In the future, practice guidelines for resuscitation might be modified as sufficient evidence becomes available. For example, different resuscitation processes may need to be applied, such as the administration of different drugs during CPR, for patients who are currently taking digoxin or statins.

In this study, we did not find any significant association between the empiric use of antiarrhythmic drugs and OHCA event survival. Vukmir *et al* reported that antiarrhythmic use was associated with decreased survival of patients with prehospital cardiac arrest. However, this study collected only data for four specific antiarrhythmic drugs (procainamide, quinidine, disopyramide, and mexiletine) and multivariate analysis was not performed to adjust for confounding factors.[@R7] Contrastingly, a retrospective study by Dries *et al* found that the use of any antiarrhythmic agents (other than β-blockers) independently increased the risk of sudden coronary death (OR=1.33, 95% CI 1.05 to 1.69, p=0.02), but β-blockers were not associated with increased risk (OR=0.75, 95% CI 0.55 to 1.03, p=0.07). Unfortunately, this study did not specify the details of antiarrhythmic drugs and also did not evaluate the resuscitation outcomes.[@R17] In our study, we collected data on all classes of antiarrhythmic drugs, which provides a more comprehensive view of the empiric use of antiarrhythmic drugs for cardiac arrest.

There were several limitations in this study. First, potential bias is inherent in the retrospective study design. Second, we did not consider certain time-related factors which can potentially confound outcomes, such as time of collapse, time interval from collapse to ROSC, and time interval from collapse to AED use; however, recall of precise time would be difficult in an emergency settings. Third, we only collected data on drugs which have been previously reported to have an association with sudden death and/or have significant cardiovascular or respiratory effects. Potential drug--drug interactions which could possibly affect the outcomes of OHCA were not assessed. Fourth, we did not consider physiological factors, such as renal and hepatic function, which could alter pharmacological effects. Finally, this study only focused on the predictors of survived events and did not consider other core outcomes, such as survival to discharge or discharge with favorable neurological outcomes. These outcomes also deserve further investigations for their association with medications preceding OHCA.

Conclusion {#s5}
==========

This study found that the continuous use of statins during the 2 weeks preceding OHCA significantly increased the likelihood of survived events. Conversely, use of digoxin was adversely associated with survived events in patients with OHCA. As pharmacotherapy plays an important role in the primary prevention of OHCA, more attention needs to be paid to medication preceding OHCA because of their potential effects on resuscitation outcomes.
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